From: Pancreatic cancer as a sentinel for hereditary cancer predisposition
Gene | HGVS Notation | Sex: Age of Onset | Carrier Weight |
---|---|---|---|
Custom 34-gene panel (n = 66) | |||
 ATM | c.7327C > G p.(R2443G) | M: 60s | 0.81 |
 ATM | c.8734A > G p.(R2912G) | F: 60s | 0.81 |
 BRCA2 | c.3873del p.(Q1291Hfs*2) | M: 50s | 1 |
 MSH6 | c.3261dup p.(F1088Lfs*5) | F: 50s | 1 |
 PALB2 | c.1240C > T p.(R414*) | F: 60s | 1 |
 STK11 | c.738C > A p.(Y246*) | M: 40s | 1 |
 | Carrier Frequency: 5.62/66 = 8.52% (3.87–17.7%) | ||
Custom 59-gene panel (n = 147) | |||
 ATM | c.1564_1565del p.(E522Ifs*43) | M: 50s | 1 |
 ATM | c.8734A > G p.(R2912G) | M: 70s | 0.81 |
 BRCA1 | c.68_69del p.(E23Vfs*17) | M: 70s | 1 |
 BRCA2 | c.3974_3975insTGCT p.(T1325Cfs*4) | M: 70s | 1 |
 BRCA2 | c.8447G > A p.(G2816D) | F: 60s | 0.81 |
 CHEK2 | c.1159A > G p.(T387A) | M: 80s | 0.81 |
 CHEK2 | c.1427C > T p.(T476 M) | F: 50s | 0.99a |
 MRE11A | c.923dupT p.(M309Hfs*8) | M: 50s | 1 |
 MRE11A | c.1516G > T p.(E506*) | F: 60s | 1 |
 MSH6 | c.3851C > T p.(T1284 M) | F: 60s | 0.94 |
 PALB2 | c.2167_2168del p.(M723Vfs*21) | M: 60sc | 1 |
 RAD50 | c.3641G > A p.(R1214H) | F: 50s | -a |
 TP53 | c.847C > T p.(R283C) | M: 60s | 0.81 |
Clinical 14-gene panel (n = 61) | |||
 ATM | c.1402_1406delAAGAG p.(K468Vfs*17) | F:40s | 1 |
 ATM | c.2426C > A p.(S809*) | F:80sd | 1 |
 ATM | c.3993 + 1G > A (splice donor) | M:70se | -b |
 BRCA2 | c.6275_6276delTT p.(L2092Pfs*7) | M:70s | 1b |
 CDKN2A | c.301G > T p.(G101 W) | F:60sf | 1 |
 CHEK2 | c.349A > G p.(R117G) | F:70s | 0.95 |
 MSH6 | c.1444C > T p.(R482*) | F:70sg | 1 |
 TP53 | c.1015G > A p.(E339K) | F:70s | 0.81 |
 | Carrier Frequency: 17.89/208 = 8.60% (5.50–13.20%) |